Synthekine key facts
as of Oct 2026- Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments.
- Synthekine is valued at approximately $500.0M as of Oct 2026 (last reported valuation).
- It has raised $288.6M; the latest was Later Stage VC in Oct 2025.
- Notable investors include RA Capital Management, Canaan Partners, Emerson Collective, Deerfield Management, Samsara BioCapital — 13 tracked in total.
- Status: Privately Held (backing).
Synthekine's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Synthekine: the Monday email on marks, rounds and moves
Synthekine funding rounds
No funding rounds for Synthekine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Synthekine
13+Synthekine valuation
Synthekine's last reported valuation was $500 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
Synthekine investors
13 investors are on record for Synthekine, including RA Capital Management, Canaan Partners, Emerson Collective and Deerfield Management. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 asset manager.
About Synthekine
Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. The company leverages immunological insights to guide targeted protein engineering and generate transformative medicines, enabling the medical community to optimize the treatment of cancer and autoimmune disorders.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2018
- Employees
- 70
- Website
- synthekine.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.